Company news

Protalix BioTherapeutics, Inc. news in 2025

Protalix BioTherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration

December 22, 2025

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

December 17, 2025

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

November 13, 2025

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

November 6, 2025

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

November 3, 2025

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

October 17, 2025

Protalix BioTherapeutics to Present at Investor Summit Virtual

September 11, 2025

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

August 14, 2025

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

August 7, 2025

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

July 21, 2025

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

June 30, 2025

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 9, 2025

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

May 5, 2025

Calls in 2025

Decks in 2025